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Abstract
Barrett’s esophagus (BE) is a very common condition. We have obtained fairly profound knowledge of the natural history of 
this condition. This results from many cross-sectional and cohort studies, many describing patients undergoing long-term 
surveillance. Their consent to use their clinical data has improved our knowledge to the benefit of these same and other 
patients. The prevalence of BE increases with age both in men and in women. This increase starts at a younger age in men 
than in women. The incidence of high-grade dysplasia and cancer in BE depends on segment length, gender, and age. The 
latter two likely indicate the duration of the presence of BE in an individual patient. Other factors that influence the incidence 
of dysplasia and cancer are smoking behavior and use of certain medications such as PPIs, statins, and NSAIDs. Surveil-
lance of BE and treatment of dysplasia can impact the incidence of and mortality due to esophageal adenocarcinoma. This 
is of major benefit to a subgroup of BE patients. The epidemiology and burden of disease ask for further efforts to develop 
targeted screening, surveillance, and intervention techniques in coming years.
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Introduction
Almost one quarter of all human cancers arise in the gastro-
intestinal tract, the predominant cancer-affected tract in the 
human body. Remarkably, nearly all these malignancies are 
for long preceded by precursor lesions that can be visualized 
in detail with modern techniques. This provides major oppor-
tunities for screening, surveillance, and targeted intervention. 
As a result, most physicians managing patients with gastroin-
testinal disorders are used to deal with premalignant lesions, 
although the actual risks associated with different conditions 
are not always fully understood. The high cancer incidence in 
the gastrointestinal tract relates to a variety of factors. These 
include surface area, tissue turnover, and frequent exposure 
to internal and external factors that may induce tissue damage 
and chronic inflammation. This is all best illustrated at the 
gastroesophageal junction, arguably the segment of the gas-
trointestinal tract with the highest cancer incidence per seg-
ment length. Of note, this remarkably high cancer incidence 
is of recent date and seems to occur in many populations 
worldwide although at different moments in time. These dif-
ferences relate to changes in lifestyle and risk factors for Bar-
rett’s esophagus (BE) and esophageal adenocarcinoma (EAC).
Epidemiology of Barrett’s Esophagus
Exposure to gastroduodenal refluxate including acid and bile 
often leads to gastroesophageal reflux disease (GERD). This 
condition is among others characterized by chronic inflamma-
tion of the lining of the lower esophagus. GERD is very com-
mon in Western populations and increasing elsewhere such as 
in the far east [2, 11]. It is the most common GI-related diagno-
sis in the USA [1]. A systematic review of 28 studies from dif-
ferent countries reported that the prevalence of GERD in adult 
populations ranged between 18 and 28% in North America, 
9–26% in Europe, 9–33% in the Middle East, and 2.5–8% in 
East Asia [2]. This prevalence had increased with an approxi-
mate 50% in 20 years. The same study also included two studies 
reporting a GERD incidence of 4.5–5.4 per 1000 person-years 
in the UK and USA [2]. This explains that acid-suppressive 
drugs, in particular proton pump inhibitors, are since long 
among the most commonly used drugs in the Western world.
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This increase in GERD is accompanied by a rapid increase 
in prevalence of Barrett’s esophagus, the main target for pre-
vention of esophageal adenocarcinoma. The exact prevalence 
of BE in different populations is difficult to assess because 
the condition by itself is asymptomatic, and a diagnosis is 
made only when an endoscopy is performed. The latter is 
usually done for persistent GERD symptoms, which creates 
a selection bias. However, there are various data that provide 
solid ground for the assumption that Barrett’s metaplasia is 
a common condition in adults in populations with a high 
prevalence of GERD. Almost 30 years ago, a first autopsy 
study reported seven (0.95%) BE cases in 733 unselected 
autopsies in the USA [12]. Only five cases were diagnosed 
at autopsy, a first indication that the majority of BE cases 
remain undiagnosed during their lifetime. Further informa-
tion on the prevalence of BE came from endoscopy studies. 
In a large Dutch primary care database covering more than 
500,000 subjects, we noted that patients were newly diag-
nosed with Barrett’s esophagus at a rate of 40.5 per 1000 
upper gastrointestinal endoscopies in 2002 [13]. This rate 
had markedly increased over time. A recent renewed analysis 
of the same, now expanded database in combination with 
similar data from the UK, showed that the rate of newly diag-
nosed BE cases had stabilized since the previous publication 
[14]. Similar changes over time are now occurring in Asia. A 
recent analysis of 51 endoscopy studies, mainly from Eastern 
Asia, including 453,147 patients noted a pooled prevalence of 
endoscopic Barrett’s esophagus of 7.8% (95% CI 5.0–12.1) 
and of histologically confirmed Barrett’s metaplasia of 1.3% 
(0.7–2.2) [15]. These data are in line with other series. It 
should be noted that these were procedures for clinical indi-
cations, and thus included the major confounder of proce-
dures being performed for GERD symptoms. In order to 
overcome this confounder, some studied the prevalence of 
BE in subjects undergoing screening colonoscopy. In such 
a study from the USA, a 6.8% prevalence was found in 961 
subjects [16]. In another US study investigating 300 subjects 
above the age of 64 years referred for screening colonoscopy, 
a 16.7% prevalence of BE was observed [17]. In a similar 
Dutch study, we observed an approximate 7% prevalence of 
Barrett’s esophagus among 382 colonoscopy screenees with 
an average age of 53 years (results unpublished).
Several population-based studies have provided further 
insights. Among 11 studies reporting the prevalence of 
upper GI pathology in general populations, three reported 
on the prevalence of Barrett’s esophagus [18]. The first was 
the Swedish Kalixanda study. Among 1000 Swedish adults 
undergoing upper gastrointestinal endoscopy as part of a 
population prevalence study, an endoscopic BE segment 
was observed in 10.3% of the subjects. In 9.9%, histology 
confirmed the presence of columnar epithelium, while spe-
cialized intestinal metaplasia was observed in 1.6% of them. 
Of those subjects, 1.1% had a short BE segment and 0.5% 
a long segment [19]. A similar study from Italy, the Loi-
ano–Monghidoro study, found a 3.6% prevalence of Bar-
rett’s esophagus in 1033 subjects, which was histologically 
confirmed in 1.3% [20]. The Chinese SILC study included 
1030 subjects, of whom 1.8% had endoscopical signs of Bar-
rett’s esophagus [21].
More detail on the prevalence of Barrett’s esophagus 
in different populations is provided by studies on age- and 
sex-related distribution of Barrett’s esophagus prevalence. A 
study from the UK on 21,899 first endoscopies observed that 
the prevalence of BE rose with 7.4% for each additional year 
of age between the age of 20 and 59 year in males. It showed 
a similar pattern albeit with a 20-year delay in females [4]. 
This pattern was confirmed in a Dutch primary care popula-
tion as well as in Northern Ireland [22, 23].
Predisposing Factors to Barrett’s Esophagus
Gastroesophageal reflux is considered the predominant risk 
factor for Barrett’s esophagus. The risk seems to correlate 
with the severity and duration of GERD. A study from 
the USA based on cross-sectional data from 683 Veterans 
Affairs patients reported that onset of GERD before the 
age of 30 years and the presence of weekly symptoms were 
together associated with a 15-fold increased risk of Barrett’s 
esophagus [3]. Other factors include male gender, white 
race, cigarette smoking, and central adiposity [4, 5]. Many 
studies have also reported an inverse correlation between 
colonization with Helicobacter pylori and presence of Bar-
rett’s esophagus [3]. These factors interplay with genetic 
predisposition. Barrett’s esophagus shows a certain degree 
of familial clustering. In a Dutch survey of 603 patients, def-
inite familial clustering was found in 7% of patients [6]. This 
was likely an underestimate of the true prevalence of familial 
clustering, since a further 44% of participants reported that 
familial co-occurrence was either unknown or likely. Recent 
large population case–control studies identified more than 
20 genetic variants predisposing for Barrett’s esophagus in 
populations of European ancestry [7, 8].
Risk Prediction
Together, this knowledge led to a range of tools to predict 
the presence of Barrett’s esophagus in specific popula-
tions. Most of these were based on demographic and clini-
cal data alone. These models tend to have fair performance 
in predicting the likelihood that a subject will have Bar-
rett’s esophagus. A recent study aimed to combine these 
with familial history [9]. Based on close to 900 Barrett’s 
cases, the authors developed a model using eight risk factors 
including age, sex, smoking, heartburn frequency, and use 
of acid suppressants. They combined this with family his-
tory. For 50-year-old subjects, the model predicted Barrett’s 
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esophagus prevalences ranging between 3 and 33% in men, 
and 0.5 and 10% in women [9]. A recent study went fur-
ther and aimed to predict the risk of Barrett’s esophagus 
and esophageal adenocarcinoma based on demographic and 
lifestyle data in combination with an individual’s genetic 
profile [10]. The authors analyzed 3288 Barrett’s cases, 
2511 patients with esophageal adenocarcinoma, and 2177 
controls from different cohorts. Subjects were assessed for 
GERD symptoms as well as age, sex, smoking habits, body 
mass index, and use of NSAIDs. Similar to previous mod-
els, these factors were moderately accurate to discriminate 
between Barrett’s cases and controls with an area under the 
curve ranging between approximately 0.64 and 0.67 for 
demographics plus lifestyle factors alone and GERD history 
alone, and 0.79 when combining both. Each individual was 
further assigned a polygenic risk score based on their num-
ber of risk alleles (0, 1, or 2) for each of 23 genetic variants 
identified as being associated with Barrett’s esophagus. For 
each variant, the allele number was weighted in relation to 
the effect estimate of the genetic variant. The sum of these 
weighted allele counts was then divided by 23 to yield one 
polygenic risk score [10]. Adding the polygenic risk score 
to the other factors only marginally increased prediction 
accuracy with an AUC of 0.799 for all factors combined. 
The authors rightfully concluded that the small contribution 
of genetic data to their prediction tool does not justify their 
clinical use.
Progression of Barrett’s Esophagus
These data are all relevant for an adequate understanding 
of the natural history of Barrett’s esophagus. They provide 
insight into the occurrence of Barrett’s metaplasia in men 
and women, and a background to determine progression 
rates to dysplasia and cancer. These two then appear closely 
linked, as we will discuss. Similar to the development of 
knowledge on the epidemiology of Barrett’s esophagus, the 
first knowledge on progression rates to dysplasia and cancer 
also came from endoscopy series, in particular from ter-
tiary care centers. One of the oldest cohorts in this respect 
was the Rotterdam cohort. It consisted of a cohort of 166 
patients diagnosed between 1973 and 1986, and followed 
since then. They first did not receive endoscopic surveil-
lance; this started in 2001. The most recent analysis of this 
cohort included 130 patients with an average age at initial 
diagnosis of 62.4 years (range 14.4–92.3 years) and an aver-
age follow-up of 14.7 years (range 2.1–32.0) [24]. Thirteen 
patients developed high-grade dysplasia (HGD) or esopha-
geal adenocarcinoma (EAC) during follow-up, correspond-
ing with a rate of 1 per 151 patient-years or 0.66% per year 
(95% CI 0.58–74). Many other studies came with similar 
data, although often with limited patient numbers and short 
duration of follow-up. Together, these expanding series were 
over time repeatedly subjected to systematic reviews and 
meta-analyses. These meta-analyses consistently reported 
progression rates to cancer varying between 2.2 and 6.3 per 
1000 patient-years when focusing on all Barrett’s patients 
[25–29]. Further reviews taught that the risk was in the low 
range for patients with non-dysplastic Barrett’s at a rate of 
3.3 (2.8–3.8) and only 1.9 per 1000 years for patients with 
short-segment BE [30]. A recent US and Dutch multicenter 
study reported no progression to high-grade dysplasia or 
cancer in 167 short-segment (< 1 cm) non-dysplastic BE 
cases [31]. In contrast to these findings in patients with 
short and non-dysplastic BE, the rate of cancer tended to 
be higher in patients with BE and low-grade dysplasia. A 
systematic review of 24 studies with 2694 patients followed 
for at least 2 years reported an annual progression rate to 
cancer of 5.4 (3.2–7.6) per 1000 years, and progression to 
high-grade dysplasia or cancer combined of 17.3 (9.9–24.7) 
per 1000 patient-years [32] (Table 1). Most of these studies 
relied on single pathologist’s evaluation per patient. Since 
the diagnosis of dysplasia is investigator dependent, more 
stringent criteria ask for confirmation of dysplasia by a 
second pathologist. This often leads to down-staging of a 
proportion of patients. This in turn may affect disease pro-
gression rates. This was illustrated by a recent study that 
re-assessed low-grade dysplastic samples of 231 BE patients 
[33]. Low-grade dysplasia was confirmed in 161 (70%); the 
remainder was mostly downgraded to no dysplasia or indefi-
nite for dysplasia. Two patients were upgraded to high-grade 
dysplasia. In patients with confirmed low-grade dysplasia, 
the subsequent incidence of high-grade dysplasia and EAC 
combined was 5.18 (3.63–7.19), and the incidence of EAC 
alone 2.51 (1.49–3.99) per 100 patient-years [33]. One study 
of 68 BE patients with low-grade dysplasia even reported 
progression to EAC alone, respectively, in combination with 
HGD in approximately 3 and 8.5% of patients per year [34].
The highest progression rates to cancer are not surpris-
ingly noted in patients with high-grade dysplasia. Deter-
mination of their progression rates is confounded by the 
fact that HGD patients form only a small minority of BE 
patients that nowadays routinely undergoes intervention 
such as endoscopic resection. This precludes determination 
Table 1  Incidence per 1000 patient-years of neoplastic progression 
among BE patients with no dysplasia (ND) and low-grade dysplasia 
(LGD)
HGD high-grade dysplasia, EAC esophageal adenocarcinoma
HGD and EAC EAC
ND 5.2 (95% CI 4.1; 6.6) [50] 3.3 (95% CI 2.8; 3.8) [30]
LGD 17.3 (95% CI 9.9; 24.7) 
[32]
5.4 (95% CI 3.2; 7.6) [32]
ND and LGD 5.8 (95% CI 4.7; 7.2) [50] 4.3 (95% CI 3.4; 5.5) [50]
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of natural progression rates to esophageal adenocarcinoma. 
Nevertheless, one systematic review included four original 
studies of 236 BE patients with HGD that were followed for 
at least 6 months without intervention. The progression rate 
to cancer in these patients with high-grade dysplasia was 
6.58 (4.97–8.19) per 100 years [35]. This frequent diagno-
sis of invasive cancer in patients with high-grade dysplasia 
firstly reflects the co-existence of these lesions and the sub-
tleties of histopathological diagnosis, and secondly likely 
also is a measure of true progression. This forms the basis 
for guideline recommendations to assess dysplastic samples 
with two pathologists, and manage high-grade dysplasia and 
cancer by means of expert high-resolution endoscopy and 
endoscopic resection if possible. This first enables further 
staging and may also form adequate treatment depending on 
histology [36–38].
Factors that Influence the Natural History 
of Barrett’s Esophagus
Barrett’s Segment Length
As mentioned, the risk of progression to HGD or EAC seems 
very low in patients with short-segment BE. Conversely, the 
risk may increase in relation to BE segment length. This 
was confirmed in a recent US study on 1175 BE patients 
followed for an average 5.5 years [39]. The risk of HGD and 
EAC combined was 0.31% per year for those with a BE seg-
ment < 3 cm and increased 1.28-fold with every extra cm to 
2.41% for those with a BE segment > 13 cm. These findings 
were supported by others [40].
Proton Pump Inhibitors
In a prospective cohort of 540 BE patients followed for 
5.2  years, treatment with a proton pump inhibitor dur-
ing follow-up was associated with an hazard ratio of 0.21 
(0.07–0.66) for progression to HGD or EAC [41]. A meta-
analysis of this and six other studies concluded that PPI use 
was associated with a 71% reduction of the risk of HGD 
or EAC [42]. The authors further noted a trend toward a 
dose–response effect with a stronger protective effect with 
longer duration of PPI therapy.
NSAIDs and Statins
Several studies reported that both NSAIDs and statins alone 
and in combination also decreased the risk for progression 
of BE [43–45]. The individual studies reported relative risks 
for NSAID and statin use alone ranging for each between 
0.45 and 0.65, with one study reporting that the combina-
tion further augmented the effect leading to a hazard ratio 
of 0.22 [44].
Tobacco Smoking
One study from Ireland reported that smoking was associ-
ated with a hazard ratio of 2.03 (1.29–3.17) for progression 
to HGD or EAC [46]. Other studies reported non-significant 
associations between smoking and BE progression.
A recent systematic review and meta-analysis combined 
these studies and confirmed that the risk of progression to 
HGD or EAC in BE patient was firstly determined by the 
presence or absence of low-grade dysplasia with an odds 
ratio of 4.2 (2.1–8.5) [47] (Table 2). The risk of progres-
sion to HGD or cancer further significantly increased with 
increasing BE segment length with an odds ratio of 1.2 
(1.1–1.3) per additional cm in length. The study further con-
firmed that use of a PPI or statin significantly decreased the 
risk of progression to HGD or cancer, while the protective 
effect of NSAID use was of borderline significance [47]. 
Finally, the systematic review confirmed that higher age and 
male sex are risk factors for disease progression. Although 
reported as separate factors, various studies have suggested 
that these are actually interrelated and together a reflection 
of the duration of presence of BE. Males on average have a 
lower age of onset of BE, and thus at any given age a higher 
likelihood of long disease duration. A Dutch cohort study 
suggested that HGD and cancer in particular occurred after 
Table 2  Patient characteristics 
and risk of neoplastic 
progression to HGD/EAC in 
Barrett’s esophagus
Patient characteristic Risk estimation
Age [47] OR 1.03 (95% CI 1.01; 1.05)
Male gender [47] OR 2.16 (95% CI 1.84; 2.53)
Length of BE segment (per additional cm) [47] OR 1.25 (95% CI 1.16; 1.36)
Proton pump inhibitors [47] OR 0.55 (95% CI 0.32; 0.96)
NSAIDs and statins  NSAIDs [44] HR 0.47 (95% CI 0.24; 0.93)
 Statins [47] OR 0.48 (95% CI 0.31; 0.73)
 Combination [44] HR 0.22 (95% CI 0.06; 0.85)
Tobacco smoking [46] HR 2.03 (95% CI 1.29; 3.17)
Low-grade dysplasia [47] OR 4.25 (95% CI 2.58; 7.0)
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an “incubation period” of at least 30 years [24]. A British 
study suggested a 17-year delay in development of BE in 
women compared to men [48]. Together, these phenomena 
can explain male gender and age as risk factors for progres-
sion to HGD and cancer [47]. 
Population Picture
Together, these data allow constructing population over-
views. This provides a picture with GERD as most common 
clinical diagnosis in Western countries. A distinct propor-
tion of them develops Barrett’s esophagus. We do not see 
Barrett’s metaplasia gradually develop over time in GERD 
patients undergoing repeat endoscopy, but we do know that 
the prevalence of BE steadily increases with age with a time 
gap between men and women. Data on the prevalence of BE 
in symptomatic patients undergoing diagnostic endoscopy 
are by definition biased. However, studies into the preva-
lence of BE in other populations such as subjects undergoing 
screening colonoscopy, and true population studies evaluat-
ing the prevalence of BE in unselected subjects provide more 
reliable information [16–21]. These studies reported a rather 
steady 3–10% prevalence of BE, with some variation above 
and below these borders. The differences without doubt in 
part relate to the population and age-group studied, as well 
as to the definition of BE. Some studies for instance reported 
on the prevalence of endoscopic signs of BE metaplasia and 
the histopathological prevalence of, respectively, columnar 
metaplasia and specialized intestinal metaplasia. If we would 
accept the 7% prevalence of BE among Dutch 50+ year olds 
as previously observed in colonoscopy screenees, this would 
translate to approximately 308,000 BE carriers among 4.4 
million subjects. With an approximate 1500 esophageal ade-
nocarcinomas per year in the same population, the annual 
incidence of EAC among all BE carriers would approximate 
0.49%.
Another approach can be based on all identified BE 
cases in the Netherlands, in combination with the fact that 
we know that no more than 5–10% of EAC patients had 
been known with BE prior to their cancer diagnosis [49]. 
In the Netherlands in 2010, close to 42,500 subjects had 
been identified by histology with BE [50]. If these indeed 
represented a maximal 10% of all BE cases, their total would 
amount to at least 425,000. Assuming that these cases in 
particular affect subjects aged 50 years and above, it would 
be equivalent with a 9% prevalence of BE in this subgroup 
of the total population. The annual 1500 cases would then 
be equivalent to an annual incidence of EAC among all BE 
carriers of approximately 0.35%.
One quickly realizes that both combinations are rough 
estimates. The beauty is that they allow providing an overall 
population picture that then can be used for public health 
discussions. The picture also makes clear that a 1% popu-
lation prevalence of BE as sometimes suggested does not 
match cancer incidence data. Again, for the Dutch situation 
this would match 44,000 BE cases among 4.4 million 50+ 
year olds. This would imply that nearly all BE cases have 
been identified in this country, and that the cancer incidence 
among these BE cases would approximate 3% per year, or 
six- to tenfold the rate of any cohort study with the exception 
of studies on HGD. Both implications are unlikely and not 
supported by the literature. These epidemiological exercises 
also illustrate the correlation between population prevalence 
of BE, cancer incidences among BE cases, and resulting 
EAC cases per year, with the latter number being the most 
solid and based on cancer registries. The given number of 
cancer cases thus translates back in the interrelated BE prev-
alence and cancer incidence.
These data were in recent years supported by three large 
population studies (Table 3). The first and largest came from 
the Netherlands and reported on 42,207 BE patients iden-
tified in the Dutch national histopathology registry [50]. 
Among patients undergoing endoscopic surveillance, the 
annual incidence of EAC was 0.4%. However, the cancer 
incidence was 0.14% overall for the total cohort when also 
including all BE patients who did not undergo surveillance. 
Two similar studies with, respectively, 11,000 Irish and 8500 
Danish patients had very similar results with cancer inci-
dences of 0.13 and 0.15% [51, 52]. These consistent data 
from three population studies in Western Europe with large 
patient numbers suggest that the overall incidence of EAC in 
unselected BE cases is low. As mentioned, this matches with 
a high prevalence of BE in the general population.
Natural History of BE and Benefits of Screening 
and Surveillance
These data are very relevant to determine optimal cancer 
prevention strategies. Modeling studies for instance showed 
that the cost efficacy of BE surveillance strongly depended 
Table 3  Population-based 
incidence studies of esophageal 
adenocarcinoma (EAC) in 
unselected patients with 
Barrett’s esophagus
Country BE patients (n) Incident 
EAC (n)
Person-years 
follow-up
EAC incidence 
(% per year)
95% 
confidence 
interval
The Netherlands [50] 42,207 337 234,821 0.14 0.12–0.16
Ireland [51] 8522 79 59,784 0.13 0.10–0.16
Denmark [52] 11,028 66 56,782 0.12 0.09–0.15
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on cancer incidence [53–56]. These modeling studies gener-
ally tend to use higher cancer incidences than reported in the 
above-mentioned population studies. Papers on BE, whether 
original studies, reviews, or guidelines, often start with state-
ments such as that EAC is the most rapidly increasing cancer 
in the world [34] and the fastest growing cause of cancer 
mortality [36]. Statements such as these find a source in the 
fact that EAC has shown a proportional dramatic increase 
in Western populations over the past 40 years. However, 
despite this proportional increase, both statements are untrue 
and likely to remain untrue for long. When looking at GI-
tract cancers alone, mortality worldwide due to gastric, colo-
rectal, liver, and pancreatic cancer remains far more common 
than mortality due to esophageal adenocarcinoma. Further, 
mortality due to colorectal, liver, and pancreatic cancer rose 
more in absolute numbers in the period of 1990–2013 than 
mortality due to esophageal cancer [57]. This is true on a 
global basis, but in Western countries alone. Even in regions 
such as North America and Western Europe with the high-
est EAC incidence, it remains a rare malignancy roughly 
making up for 1% of all cancers [58]. Unfortunately, 5-year 
survival rates remain poor with only 20% [58]. This survival 
only slowly increased over the past 40 years.
All together, we are thus faced with a major clinical and 
public health problem. At a time of decreasing prevalence 
of Helicobacter pylori and increasing prevalence of obesity, 
we are faced with GERD affecting a substantial part of the 
adult population worldwide. A considerable proportion of 
GERD-affected subjects develop BE. This means that many 
countries will have to take into account that many of their 
50+ year olds carry BE, even when undiagnosed in most of 
them. A small proportion of these subjects annually progress 
to HGD and EAC. At an early stage, these conditions can 
be treated by ablative techniques with limited burden and 
risks. However, at an advanced stage, EAC requires invasive 
treatment with considerable burden, costs, and mortality. In 
recent years, treatment for invasive EAC has shown marked 
improvements with introduction of presurgical chemora-
diotherapy [59]. Further efforts are ongoing to see whether 
chemoradiotherapy can provide curative options and thus 
replace surgery in certain EAC patients [60]. Nevertheless, 
prevention and early detection remain by far the most attrac-
tive strategy to manage EAC. Together, the high prevalence 
of BE and the low cancer incidence among unselected BE 
cases, versus the burden of treatment and low survival of 
EAC ask for smart strategies to select BE patients who are 
most likely to benefit from surveillance and intervention. 
These do not include short-segment BE cases, nor the major-
ity of those without dysplasia [61]. A recent multicenter 
study based on 2697 BE patients developed a scoring sys-
tem based on gender, smoking status, BE length, and the 
presence of low-grade dysplasia to classify patients at low, 
intermediate, and high risk [62]. During a 7-year follow-up, 
progression to HGD and EAC occurred in 0.5, 4.6, and 
12.3%, respectively.
Conclusions
With many patients undergoing long-term surveillance and 
providing consent to use their data to improve our knowledge 
and benefit others, and many researchers worldwide report-
ing their analyses of these data, we have obtained a major 
understanding of the natural history of BE. BE is a common 
condition, with a prevalence increasing with age in men and 
women, although with a delay in women. The incidence of 
HGD and cancer in BE depends on segment length, gen-
der, and age, both likely a marker for the length of presence 
of BE, the presence or absence of low-grade dysplasia, and 
other factors such as smoking behavior and use of certain 
medications such as PPIs, statins, and NSAIDs. Targeted use 
of surveillance and intervention can impact the incidence and 
mortality due to EAC and is of major benefit to a subgroup 
of BE patients. The epidemiology and burden of disease ask 
for further efforts to develop targeted screening, surveillance, 
and intervention techniques in coming years.
Key Messages
• The prevalence of GERD has increased with approxi-
mately 50% in the last 20 years.
• The presence of BE has increased simultaneously, in 
Western countries leading to an estimated population 
prevalence reaching 3–10%.
• GERD, male gender, white race, cigarette smoking, and 
central adiposity are the most common risk factors for 
Barrett’s esophagus.
• Women develop BE at a later age than men.
• Neoplastic progression in BE depends on age, gender, 
segment length, use of proton pump inhibitors, NSAIDs 
and statins, tobacco smoking, and the presence of dys-
plasia.
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